The c.1-260C>T promoter variant of CD14 but not the c.896A>G (p.D299G) variant of toll-like receptor 4 (TLR4) genes is associated with inflammatory bowel disease

Digestion

Volumn 76, Issue 3-4, 2007, Pages 196-202

  Baumgart, Daniel C ^a   Büning, Carsten ^a   Geerdts, Lars ^a   Schmidt, Hartmut H ^a   Genschel, Janine ^a   Fiedler, Thomas ^a   Gentz, Enno ^a   Molnar, Tomas ^b   Nagy, Ferenc ^b   Lonovics, Janos ^b   Lochs, Herbert ^a   Wiedenmann, Bertram ^a   Nickel, Renate ^a   Witt, Heiko ^a   Dignass, Axel ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Antigen presentation; Antigen presenting cells; Crohn's disease; Dendritic cells; IBD; Innate immunity; Macrophages; Pattern recognition receptor; Single nucleotide variant (polymorphism); Toll like receptor; Ulcerative colitis

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CD14 ANTIGEN; TOLL LIKE RECEPTOR 4;

ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; GERMANY; HOST PATHOGEN INTERACTION; HUMAN; HUNGARY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN VARIANT; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; ANTIGENS, CD14; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RETROSPECTIVE STUDIES; TOLL-LIKE RECEPTOR 4;

EID: 40449140459     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112646     Document Type: Article

References (40)

1. Strober W, Fuss I, Mannon P: The fundamental basis of inflammatory bowel disease. J Clin Invest 2007;117:514-521.
2. Gaya DR, Russell RK, Nimmo ER, Satsangi J: New genes in inflammatory bowel disease: lessons for complex diseases? Lancet 2006;367:1271-1284.
3. Williams CN, Kocher K, Lander ES, Daly MJ, Rioux JD: Using a genome-wide scan and meta-analysis to identify a novel IBD locus and confirm previously identified IBD loci. Inflamm Bowel Dis 2002;8:375-381.
4. van Heel DA, Fisher SA, Kirby A, Daly MJ, Rioux JD, Lewis CM: Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1,952 affected relative pairs. Hum Mol Genet 2004;13:763-770.
5. Büning C, Genschel J, Bühner S, Krüger S, Kling K, Dignass AU, Baier P, Bochow B, Ockenga J, Schmidt HH, Lochs H: Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther 2004;19:1073-1078.
6. Cummings JR, Jewell DP: Clinical implications of inflammatory bowel disease genetics on phenotype. Inflamm Bowel Dis 2005;11:56-61.
7. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee A, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-1463.
8. Baumgart DC, Dignass AU: Intestinal barrier function. Curr Opin Clin Nutr Metab Care 2002;5:685-694.
9. Delves PJ, Roitt IM: The immune system. First of two parts. N Engl J Med 2000;343:37-49.
10. Delves PJ, Roitt IM: The immune system. Second of two parts. N Engl J Med 2000;343:108-117.
11. Iwasaki A: Mucosal dendritic cells. Annu Rev Immunol 2007;25:381-418.
12. Iwasaki A, Medzhitov R: Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-995.
13. Meylan E, Tschopp J, Karin M: Intracellular pattern recognition receptors in the host response. Nature 2006;442:39-44.
14. Cario E, Rosenberg IM, Brandwein SL, Beck PL, Reinecker HC, Podolsky DK: Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors. J Immunol 2000;164:966-972.
15. Cario E, Podolsky DK: Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;68:7010-7017.
16. Hart AL, Al-Hassi HO, Rigby RJ, Bell SJ, Emmanuel AV, Knight SC, Kamm MA, Stagg AJ: Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 2005;129:50-65.
17. Baumgart DC, Carding SR: Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-1640.
18. Barnes PJ, Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071.
19. Carter MJ, Lobo AJ, Travis SP; IBD Section, British Society of Gastroenterology: Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(suppl 5):V1-V16.
20. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Pena AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(suppl A):5-36.
21. Büning C, Geerdts L, Fiedler T, Gentz E, Pitre G, Reuter W, Luck W, Bühner S, Molnar T, Nagy F, Lonovics J, Dignass AU, Landt O, Nickel R, Genschel J, Lochs H, Schmidt HH, Witt H: DLG5 variants in inflammatory bowel disease. Am J Gastroenterol 2006;101:786-792.
22. Kraus TA, Toy L, Chan L, Childs J, Mayer L: Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease. Gastroenterology 2004;126:1771-1778.
23. Strober W, Fuss IJ, Blumberg RS: The immunology of mucosal models of inflammation. Annu Rev Immunol 2002;20:495-549.
24. Mayer L, Shao L: Therapeutic potential of oral tolerance. Nat Rev Immunol 2004;4:407-419.
25. Tamboli CP, Neut C, Desreumaux P, Colombel JF: Dysbiosis as a prerequisite for IBD. Gut 2004;53:1057.
26. Sartor RB: Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;126:1620-1633.
27. Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, Fort M, Hershberg RM: Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004;113:1296-1306.
28. Lu J, Wang A, Ansari S, Hershberg RM, McKay DM: Colonic bacterial superantigens evoke an inflammatory response and exaggerate disease in mice recovering from colitis. Gastroenterology 2003;125:1785-1795.
29. Kullberg MC, Andersen JF, Gorelick PL, Caspar P, Suerbaum S, Fox JG, Cheever AW, Jankovic D, Sher A: Induction of colitis by a CD4+ T cell clone specific for a bacterial epitope. Proc Natl Acad Sci USA 2003;100:15830-15835.
30. Hernandez GA, Appleyard CB: Bacterial load in animal models of acute and chronic 'reactivated' colitis. Digestion 2003;67:161-169.
31. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-606.
32. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
33. Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, Frenzel H, King K, Hasselmeyer A, MacPherson AJ, Bridger S, van Deventer S, Forbes A, Nikolaus S, Lennard-Jones JE, Foelsch UR, Krawczak M, Lewis C, Schreiber S, Mathew CG: Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001;357:1925-1928.
34. Klein W, Tromm A, Griga T, Folwaczny C, Hocke M, Eitner K, Marx M, Duerig N, Epplen JT: Interaction of polymorphisms in the CARD15 and CD14 genes in patients with Crohn disease. Scand J Gastroenterol 2003;38:834-836.
35. Klein W, Tromm A, Griga T, Fricke H, Folwaczny C, Hocke M, Eitner K, Marx M, Duerig N, Epplen JT: A polymorphism in the CD14 gene is associated with Crohn disease. Scand J Gastroenterol 2002;37:189-191.
36. Obana N, Takahashi S, Kinouchi Y, Negoro K, Takagi S, Hiwatashi N, Shimosegawa T: Ulcerative colitis is associated with a promoter polymorphism of lipopolysaccharide receptor gene, CD14. Scand J Gastroenterol 2002;37:699-704.
37. Gazouli M, Mantzaris G, Kotsinas A, Zacharatos P, Papalambros E, Archimandritis A, Ikonomopoulos J, Gorgoulis VG: Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. World J Gastroenterol 2005;11:681-685.
38. Okayama N, Fujimura K, Suehiro Y, Hamanaka Y, Fujiwara M, Matsubara T, Maekawa T, Hazama S, Oka M, Nohara H, Kayano K, Okita K, Hinoda Y: Simple genotype analysis of the Asp299Gly polymorphism of the Toll-like receptor-4 gene that is associated with lipopolysaccharide hyporesponsiveness. J Clin Lab Anal 2002;16:56-58.
39. Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot T, Quertinmont E, Abramowicz M, Van Gossum A, Devière J, Rutgeerts P: Deficient host-bacteria interactions in inflammatory bowel disease? The Toll-like receptor (TLR)-4 Asp-299Gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004;53:987-992.
40. Lakatos PL, Lakatos L, Szalay F, Willheim-Polli C, Osterreicher C, Tulassay Z, Molnar T, Reinisch W, Papp J, Mozsik G, Ferenci P; Hungarian IBD Study Group: Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations. World J Gastroenterol 2005;11:1489-1495.